ENOV earnings

Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-987

Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter 2025 Financial Results Enovis' fo

Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on Thursday, February 26th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, pleas

Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus

Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com. Additionally, the company also announced it will participate in the following investor conferences: UBS Global Healthcare Conference: Damien McD

Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter

Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 6

Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion Fourth-quarter Reconstructive sales grew 59% year-over-year on a reported basis and 10% on a Comparable Sales basis Exceeded year one commercial and integration plans for Lima Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. F

Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the "Board") of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO.  As part of the Company's succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to serve as the Company's next CEO. Upon th

Wilmington, DE, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2024 financial results on Wednesday, February 26th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call as well as a webcast can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, ple

Continued commercial momentum with third-quarter sales growth of 21% on a reported basis and strong adjusted EBITDA margin expansionReconstructive sales grew 57% Y/Y on a reported basis and 9% on a Comparable basisReported third-quarter net loss from continuing operations of $0.61 per share, adjusted net income per diluted share of $0.73, up +30% Y/Y Wilmington, DE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended September 27, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:3

Wilmington, DE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715

Continued strong momentum with second-quarter sales growth of 23% on a reported basis and strong adjusted margin expansionReported second-quarter net loss from continuing operations of $0.34 per share with adjusted net income per diluted share of $0.62Advanced strategic goals with solid first half of 2024, slightly ahead of expectations, and set up to accelerate in the second half of the year Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 28, 2024. The Company will host an investor conference call and live webcast to discuss

Wilmington, DE, July 25, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced a change in the scheduling of its upcoming earnings results conference call. The call will still take place on August 7, 2024, but will now be held at 8:00 a.m. Eastern Time, instead of the previously announced time. There is no change to the date, the dial-in or webcasting information. A presentation related to the call will be available on ir.enovis.com. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 6

Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (Internati

Strong start to the year with sales growth of 27% on a reported basis and strong adjusted margin expansionReported first-quarter net loss from continuing operations of $1.32 per share with adjusted earnings per diluted share of $0.50 Wilmington, DE, May 02, 2024 (GLOBE NEWSWIRE) --   Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended March 29, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:00 am ET. First Quarter 2024 Financial Results Enovis' first-quarter net sales of $516 million grew 27% on a reported basi

Wilmington, DE, April 17, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2024 financial results on Thursday, May 2, 2024 at 8:00 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the "Investors" section. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317

Continued strong momentum with fourth-quarter sales growth of 11%, organic growth of 8% Reported fourth-quarter net income from continuing operations of $0.05 per share with adjusted earnings per diluted share of $0.79Entering 2024 with strong operating momentum and an exciting slate of new product launches Wilmington, DE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter and Fiscal Ye

Wilmington, DE, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2023 financial results on Thursday, February 22, 2024 at 8:30AM ET and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the "Investors" section. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 3

Continued strong momentum with third quarter sales growth of 9% and strong adjusted EBITDA margin expansionOrganic growth of 10% in Recon and 4% in P&RReported a third quarter net loss from continuing operations of $0.36 per share with adjusted earnings per diluted share of $0.56Increased full-year growth and profit outlook Wilmington, DE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended September 29, 2023. The Company will host an investor conference call and live webcast to discuss these results today at 8:00 am ET.

Wilmington, DE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its third quarter 2023 financial results on Tuesday, November 7, 2023 at 8:00 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the "Investors" section. Conference call/Webcast Information    Investors can access a live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 31

Creating a high-growth, global reconstruction leader with ~$1 billion in annual revenueAttractive margin profile and meaningful synergies expected to increase profitability Wilmington, DE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV, "Enovis" or the "Company"))), an innovation-driven, medical technology growth company, today announced a definitive agreement to acquire LimaCorporate S.p.A. ("Lima"), a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions. The acquisition has an enterprise value of approximately €800 million, consisting of a €700 million cash payment at closing and €100 million in

Continued strong momentum with second quarter sales growth of 8% and strong EBITDA margin expansionOrganic growth of 17% in Recon and 4% in P&R Reported a second quarter net loss from continuing operations of $0.27 per share with adjusted earnings per diluted share of $0.61 Wilmington, DE, Aug. 03, 2023 (GLOBE NEWSWIRE) -- —Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 30, 2023. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2023 Financial Results Enovis' second quarter net sales of $

Wilmington, DE, July 11, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that it will host an investor conference call and live webcast to discuss its second quarter 2023 financial results on Thursday August 3, 2023 at 8:30 a.m. Eastern Time and will issue a press release earlier that morning. A presentation related to the call will be available at www.enovis.com in the "Investors" section. Conference call/Webcast Information    Investors can access a live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 630-1956 (U.S. callers) and (412) 317-1837 (

Strong start to the year with sales growth of 8%, organic growth of 9% and strong EBITDA margin expansionOrganic growth of 9% reflects 19% organic growth in Recon and 4% organic growth in P&R Reported a first quarter net loss from continuing operations of $0.42 per share with adjusted earnings per diluted share of $0.44Increased 2023 financial outlook Wilmington, DE, May 04, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended March 31, 2023. The Company will host an investor conference call and live webcast to discuss these results today at 8:30

Wilmington, DE, April 13, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2023 financial results on Thursday, May 4, 2023 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the "Investors" section. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 630-1956 (U.S. callers) and (412) 317-1837 (Inter

Wilmington, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.    Fourth Quarter and Fiscal Year 2022 Financial Results Enovis' fourth quarter net sales of $409 million grew 2% from the prior year, reflecting 5% organic growth offset by a 3% currency headwind. Sales in the Reconstructive segment grew 12%, and 14% on an organic basis, and its Prevention and Recovery segment declined 2%

Wilmington, DE, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 at 8:30AM ET and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the "Investors" section. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 630-1956 (U.S. callers) and

Grew sales to $384 million, including 7% organic growth over the prior year quarter, with double-digit growth performance across its Reconstructive segmentReported a net loss of $(1.22) per diluted share from continuing operations and increased its adjusted earnings per share 34% to $0.59Expanded core margins and extended its innovation momentum with several new product launches Wilmington, DE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced its financial results for the third quarter of 2022. The Company will host an investor conference call and live webcast to discus

Wilmington, DE, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2022 financial results on Wednesday, November 2, 2022 at 8:00AM ET and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the "Investors" section. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9871 (U.S. callers) and (646) 307-1963 (Inter

Sales of $395 million include 11% reported growth, 3% organic growth and 5% sales-per-day growthReported operating income of $6 million, while adjusted EBITDA increased 11% to $56 millionReported earnings per diluted share from continuing operations of $2.21; expanded adjusted earnings per share 44% to $0.59.Full year adjusted EBITDA and EPS outlooks updated to reflect currency impact and Q2 tax benefit Wilmington, DE, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced its financial results for the second quarter of 2022. The company will host an investor conference call and live web

Wilmington, DE, July 12, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2022 financial results on Thursday, August 4, 2022 at 8:00AM ET and issue an earnings press release earlier that morning. A presentation related to the call will be available on www.enovis.com in the "Investors" section. Conference call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9871 (U.S. callers) and (646) 307-1963 (Internation

Wilmington, DE, May 10, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE:ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, today announced its adjusted stand-alone financial results for the first quarter of 2022.   At the beginning of its second quarter on April 4, 2022, Colfax Corporation spun-off its industrial manufacturing business, ESAB Corporation, in a tax-free distribution to shareholders and renamed itself Enovis. First Quarter Financial Results Enovis reported strong first quarter stand-alone sales of $375 million, an increase of 21%, or 7% on an organic basis versus the comparable prior year period. Reconstructive (Recon) sal

Wilmington, DE, April 14, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE:ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, today announced that it will issue a press release on the morning of Tuesday, May 10, 2022 providing pro forma financial results for the first quarter of fiscal year 2022. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 3684428 and through a webcast via Enovis' website www.enovis.com under the "In